The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer

For decades, HER2-positive breast cancer was associated with poor outcomes and higher mortality rates than other breast cancer subtypes. However, the advent of Trastuzumab (Herceptin) has significantly changed the treatment paradigm of patients afflicted with HER2-positive breast cancer. The discove...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Aena, Unni, Nisha, Peng, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464074/
https://www.ncbi.nlm.nih.gov/pubmed/32731409
http://dx.doi.org/10.3390/cancers12082081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464074/
https://www.ncbi.nlm.nih.gov/pubmed/32731409
http://dx.doi.org/10.3390/cancers12082081

Ejemplares similares